(Q82244856)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20010899%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

review article

1 reference

title

Genomic markers for decision making: what is preventing us from using markers? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20010899%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

Vicky M Coyle

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20010899%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Patrick G Johnston

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20010899%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

15 December 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20010899%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20010899%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20010899%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20010899%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

90-97

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20010899%20AND%20SRC:MED&resulttype=core&format=json

Clinical application of cDNA microarrays in oncology

15 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Gene-expression signatures in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Fundamentals of experimental design for cDNA microarrays

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Laser capture microdissection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

DNA microarrays in clinical oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Expression profiling with RNA from formalin-fixed, paraffin-embedded material

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

A novel approach for reliable microarray analysis of microdissected tumor cells from formalin-fixed and paraffin-embedded colorectal cancer resection specimens.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Optimization of RNA extraction from formalin-fixed, paraffin-embedded lymphoid tissues.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

RNA expression analysis from formalin fixed paraffin embedded tissues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Preliminary comparison of quantity, quality, and microarray performance of RNA extracted from formalin-fixed, paraffin-embedded, and unfixed frozen tissue samples

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

A cut-off based approach for gene expression analysis of formalin-fixed and paraffin-embedded tissue samples

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Common denominator genes that distinguish colorectal carcinoma from normal mucosa.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Gene expression profiles of different clinical stages of colorectal carcinoma: toward a molecular genetic understanding of tumor progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Transcriptional census of 36 microdissected colorectal cancers yields a gene signature to distinguish UICC II and III.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Whole genome analysis for liver metastasis gene signatures in colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Differential gene expression profiles of metastases in paired primary and metastatic colorectal carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Microarray analysis and tumor classification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

DNA microarrays and data analysis: an overview

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

How large a training set is needed to develop a classifier for microarray data?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Clinical trial design for microarray predictive marker discovery and assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Validation of biomarker-based risk prediction models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Use of genomic signatures in therapeutics development in oncology and other diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Statistical issues in translational cancer research

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Minimum information about a microarray experiment (MIAME)-toward standards for microarray data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Evaluation of DNA microarray results with quantitative gene expression platforms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Reproducible and reliable microarray results through quality control: good laboratory proficiency and appropriate data analysis practices are essential

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

The use of genomics in clinical trial design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Challenges of microarray data and the evaluation of gene expression profile signatures

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.214

Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20010899

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Gene expression profiling of primary tumor cell populations using laser capture microdissection, RNA transcript amplification, and GeneChip microarrays.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20010899

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2009.214

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20010899%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference